vs

Side-by-side financial comparison of Emerald Holding, Inc. (EEX) and MEDIFAST INC (MED). Click either name above to swap in a different company.

Emerald Holding, Inc. is the larger business by last-quarter revenue ($132.7M vs $75.1M, roughly 1.8× MEDIFAST INC). On growth, Emerald Holding, Inc. posted the faster year-over-year revenue change (24.3% vs -36.9%). Emerald Holding, Inc. produced more free cash flow last quarter ($11.7M vs $-6.6M). Over the past eight quarters, Emerald Holding, Inc.'s revenue compounded faster (-0.3% CAGR vs -34.4%).

TVS Emerald Haven Realty Limited is an Indian real estate development company headquartered in Chennai, Tamil Nadu. A subsidiary of TVS Holdings, it specializes in sustainable residential communities and urban development projects.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

EEX vs MED — Head-to-Head

Bigger by revenue
EEX
EEX
1.8× larger
EEX
$132.7M
$75.1M
MED
Growing faster (revenue YoY)
EEX
EEX
+61.1% gap
EEX
24.3%
-36.9%
MED
More free cash flow
EEX
EEX
$18.3M more FCF
EEX
$11.7M
$-6.6M
MED
Faster 2-yr revenue CAGR
EEX
EEX
Annualised
EEX
-0.3%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EEX
EEX
MED
MED
Revenue
$132.7M
$75.1M
Net Profit
$-30.2M
Gross Margin
69.4%
Operating Margin
-11.8%
-10.4%
Net Margin
-22.8%
Revenue YoY
24.3%
-36.9%
Net Profit YoY
-692.2%
EPS (diluted)
$-0.15
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EEX
EEX
MED
MED
Q4 25
$132.7M
$75.1M
Q3 25
$77.5M
$89.4M
Q2 25
$105.5M
$105.6M
Q1 25
$147.7M
$115.7M
Q4 24
$106.8M
$119.0M
Q3 24
$72.6M
$140.2M
Q2 24
$86.0M
$168.6M
Q1 24
$133.4M
$174.7M
Net Profit
EEX
EEX
MED
MED
Q4 25
$-30.2M
Q3 25
$-14.4M
$-2.3M
Q2 25
$-1.4M
$2.5M
Q1 25
$15.3M
$-772.0K
Q4 24
$5.1M
Q3 24
$-11.1M
$1.1M
Q2 24
$-2.8M
$-8.2M
Q1 24
$11.0M
$8.3M
Gross Margin
EEX
EEX
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
EEX
EEX
MED
MED
Q4 25
-11.8%
-10.4%
Q3 25
-10.1%
-4.6%
Q2 25
9.7%
-1.0%
Q1 25
24.2%
-1.1%
Q4 24
19.5%
0.6%
Q3 24
-6.5%
1.5%
Q2 24
7.4%
-4.7%
Q1 24
18.2%
4.5%
Net Margin
EEX
EEX
MED
MED
Q4 25
-22.8%
Q3 25
-18.6%
-2.5%
Q2 25
-1.3%
2.3%
Q1 25
10.4%
-0.7%
Q4 24
4.8%
Q3 24
-15.3%
0.8%
Q2 24
-3.3%
-4.8%
Q1 24
8.2%
4.8%
EPS (diluted)
EEX
EEX
MED
MED
Q4 25
$-0.15
$-1.64
Q3 25
$-0.07
$-0.21
Q2 25
$-0.01
$0.22
Q1 25
$0.08
$-0.07
Q4 24
$0.01
$0.08
Q3 24
$-0.05
$0.10
Q2 24
$-0.03
$-0.75
Q1 24
$0.00
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EEX
EEX
MED
MED
Cash + ST InvestmentsLiquidity on hand
$100.9M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$338.8M
$198.9M
Total Assets
$1.2B
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EEX
EEX
MED
MED
Q4 25
$100.9M
$167.3M
Q3 25
$95.4M
$173.5M
Q2 25
$156.4M
$162.7M
Q1 25
$276.8M
$164.6M
Q4 24
$194.8M
$162.3M
Q3 24
$188.9M
$170.0M
Q2 24
$193.2M
$163.5M
Q1 24
$186.8M
$156.4M
Stockholders' Equity
EEX
EEX
MED
MED
Q4 25
$338.8M
$198.9M
Q3 25
$369.5M
$214.7M
Q2 25
$389.4M
$216.0M
Q1 25
$392.1M
$211.0M
Q4 24
$385.9M
$210.1M
Q3 24
$391.1M
$207.3M
Q2 24
$407.6M
$205.3M
Q1 24
$-90.7M
$211.0M
Total Assets
EEX
EEX
MED
MED
Q4 25
$1.2B
$248.0M
Q3 25
$1.2B
$268.2M
Q2 25
$1.2B
$269.3M
Q1 25
$1.2B
$280.0M
Q4 24
$1.0B
$284.2M
Q3 24
$1.1B
$291.2M
Q2 24
$1.1B
$293.5M
Q1 24
$1.1B
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EEX
EEX
MED
MED
Operating Cash FlowLast quarter
$12.3M
$-5.3M
Free Cash FlowOCF − Capex
$11.7M
$-6.6M
FCF MarginFCF / Revenue
8.8%
-8.8%
Capex IntensityCapex / Revenue
0.5%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.4M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EEX
EEX
MED
MED
Q4 25
$12.3M
$-5.3M
Q3 25
$1.8M
$12.1M
Q2 25
$15.9M
$-3.4M
Q1 25
$12.6M
$3.4M
Q4 24
$20.6M
$-4.9M
Q3 24
$9.1M
$9.1M
Q2 24
$9.8M
$13.1M
Q1 24
$7.3M
$7.3M
Free Cash Flow
EEX
EEX
MED
MED
Q4 25
$11.7M
$-6.6M
Q3 25
$1.5M
$10.8M
Q2 25
$15.8M
$-4.8M
Q1 25
$12.4M
$1.9M
Q4 24
$19.9M
$-7.2M
Q3 24
$9.0M
$7.7M
Q2 24
$9.6M
$11.1M
Q1 24
$7.0M
$5.4M
FCF Margin
EEX
EEX
MED
MED
Q4 25
8.8%
-8.8%
Q3 25
1.9%
12.0%
Q2 25
15.0%
-4.5%
Q1 25
8.4%
1.6%
Q4 24
18.6%
-6.1%
Q3 24
12.4%
5.5%
Q2 24
11.2%
6.6%
Q1 24
5.2%
3.1%
Capex Intensity
EEX
EEX
MED
MED
Q4 25
0.5%
1.8%
Q3 25
0.4%
1.5%
Q2 25
0.1%
1.3%
Q1 25
0.1%
1.3%
Q4 24
0.7%
1.9%
Q3 24
0.1%
1.0%
Q2 24
0.2%
1.1%
Q1 24
0.2%
1.1%
Cash Conversion
EEX
EEX
MED
MED
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
0.82×
Q4 24
4.04×
Q3 24
8.04×
Q2 24
Q1 24
0.66×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EEX
EEX

Connections Segment$121.9M92%
Commerce Segment$5.5M4%
Content$5.3M4%

MED
MED

Segment breakdown not available.

Related Comparisons